613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy

BACKGROUND: Dalbavancin, a lipoglycopeptide with prolonged half-life targeting Gram-positive organisms, is approved for treatment of acute bacterial skin and soft tissue infection. It reduces hospital duration in patients with barriers to short-term rehabilitation or outpatient parenteral antimicrob...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuan, Jessica, Kayani, Jehanzeb, Fisher, Ann, Kotansky, Brian, Dembry, Louise, Datta, Rupak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643939/
http://dx.doi.org/10.1093/ofid/ofab466.811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643939/
http://dx.doi.org/10.1093/ofid/ofab466.811

Ejemplares similares